Boston Scientific Corporation (BSX) financial statements and ratios from SEC XBRL: revenue $20.07B (TTM), net margin 14.4%, revenue growth 7.5% YoY, P/E 19.5. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $20.07B |
| Net Margin | 14.4% |
| Revenue Growth (YoY) | 7.5% |
| EPS Growth (YoY) | 14.8% |
| FCF Growth (YoY) | 28.4% |
| P/E Ratio | 19.5 |
| EV / EBITDA | 12.0 |
| Price / Book | 2.84 |
| Price / Sales | 3.41 |
| FCF Yield | 3.7% |
| DCF Value (model) | $33.48 |
| DCF Upside vs Price | -32.2% |
| Altman Z-Score | 3.29 (safe) |
| Piotroski F-Score | 8/9 |
| Sector P/E (Healthcare) | 21.6 |
BSX overview · BSX earnings · BSX KPIs · BSX investor relations · BSX ownership · BSX peers · BSX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.